A mathematical model of vaccination against HIV to prevent the development of AIDS
- 22 November 1991
- journal article
- Published by The Royal Society in Proceedings Of The Royal Society B-Biological Sciences
- Vol. 246 (1316) , 141-146
- https://doi.org/10.1098/rspb.1991.0136
Abstract
Vaccination and post-exposure immunization against the human immunodeficiency viruses (HIV-1 and HIV-2) faces the problem of the extensive genetic and antigenic variability of these viruses. This raises the question of what fraction of all possible antigen strains of the virus must be recognized by the immune response to a vaccine to prevent development of acquired immunodeficiency disease (AIDS). The success of a vaccine can depend on the variability of the target epitopes. The different HIV variants must be suppressed faster than new escape mutants can be produced. In this paper the antigenic variation of HIV during an individual infection is described by a stochastic process. The central assumption is that antigenic drift is important for the virus to survive immunological attack and to establish a persistent infection that leads to the development of AIDS after a long incubation period. The mathematical analysis reveals that the fraction of antigenic variants recognized by the immune response, that is induced by a successful immunogen, must exceed 1 - 1/R, where R is the diversification rate of the virus population. This means that if each HIV strain can produce, on average, five new escape mutants, then more than 80% of the possible variants must be covered by the immunogen. A generic result of the model is that, no matter how immunogenic a vaccine is, it will fail if it does not enhance immune attack against a sufficiently large fraction of strains. Furthermore, it is shown that the timing of the application of post-exposure immunization is important.Keywords
This publication has 22 references indexed in Scilit:
- HIV mutation rateNature, 1990
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989
- Characterization of HIV-1 neutralization escape mutantsAIDS, 1989
- Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolationsCell, 1989
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989
- Type-Restricted Neutralization of Molecular Clones of Human Immunodeficiency VirusScience, 1988
- Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.Proceedings of the National Academy of Sciences, 1988
- Theory of an immune system retrovirus.Proceedings of the National Academy of Sciences, 1986
- Genetic Variation in HTLV-III/LAV Over Time in Patients with AIDS or at Risk for AIDSScience, 1986
- Genomic changes associated with antigenic variation of visna virus durig persistent infection.Proceedings of the National Academy of Sciences, 1980